NASDAQ:SNSS - Sunesis Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $9.00
  • Forecasted Upside: 69.17 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.32
▲ +1.04 (24.30%)
1 month | 3 months | 12 months
Get New Sunesis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNSS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNSS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$9.00
▲ +69.17% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Sunesis Pharmaceuticals in the last 3 months. The average price target is $9.00, with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a 69.17% upside from the last price of $5.32.
Hold
The current consensus among 4 investment analysts is to hold stock in Sunesis Pharmaceuticals. This rating has held steady since May 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/15/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/14/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021OppenheimerUpgradeMarket Perform ➝ Outperform$12.00Low
i
2/23/2021OppenheimerUpgradeMarket Perform ➝ Outperform$12.00High
i
8/12/2020OppenheimerReiterated RatingHoldMedium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
6/23/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
i
5/8/2020HC WainwrightLower Price TargetNeutral$10.00 ➝ $5.00Low
i
3/11/2020HC WainwrightBoost Price TargetNeutral$5.00 ➝ $10.00High
i
3/11/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$30.00 ➝ $10.00High
i
3/10/2020CowenReiterated RatingHoldHigh
i
12/5/2019CowenReiterated RatingHoldHigh
i
Rating by Marc Frahm at Cowen Inc
11/13/2019HC WainwrightReiterated RatingNeutral ➝ HoldHigh
i
Rating by Andrew Fein at HC Wainwright
8/9/2019HC WainwrightReiterated RatingHold$15.00High
i
Rating by Andrew Fein at HC Wainwright
6/17/2019HC WainwrightReiterated RatingHold$20.00High
i
Rating by A. Fein at HC Wainwright
6/16/2019CowenReiterated RatingHoldMedium
i
Rating by Marc Frahm at Cowen Inc
3/12/2019HC WainwrightReiterated RatingHold$5.00Low
i
Rating by A. Fein at HC Wainwright
3/8/2019OppenheimerSet Price TargetBuy$60.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
12/20/2018HC WainwrightInitiated CoverageNeutral ➝ Neutral$5.00High
i
Rating by A. Fein at HC Wainwright
5/8/2018CowenReiterated RatingHoldHigh
i
3/8/2018Cantor FitzgeraldReiterated RatingHold$40.00High
i
Rating by Mara Goldstein at Cantor Fitzgerald
12/14/2017OppenheimerInitiated CoverageBuy$70.00Low
i
12/11/2017Cantor FitzgeraldSet Price TargetHold$30.00High
i
Rating by Mara Goldstein at Cantor Fitzgerald
12/11/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$28.60 ➝ $24.80High
i
12/5/2017Cantor FitzgeraldSet Price TargetHold$30.00High
i
Rating by Mara Goldstein at Cantor Fitzgerald
12/5/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$27.00 ➝ $20.00High
i
11/21/2017OppenheimerInitiated CoverageOutperform$70.00N/A
i
11/20/2017UBS GroupInitiated CoverageOutperformN/A
i
11/2/2017CowenReiterated RatingHoldN/A
i
9/27/2017Cantor FitzgeraldReiterated RatingHold$30.00Low
i
7/27/2017Cantor FitzgeraldReiterated RatingHold$30.00Low
i
5/2/2017Cantor FitzgeraldReiterated RatingHold$30.00High
i
Rating by M. Goldstein at Cantor Fitzgerald
12/28/2016Cantor FitzgeraldDowngradeBuy ➝ HoldN/A
i
Rating by M. Goldstein at Cantor Fitzgerald
11/3/2016CowenReiterated RatingHoldN/A
i
9/12/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by mara goldstein at Cantor Fitzgerald
9/12/2016CowenReiterated RatingHoldN/A
i
7/29/2016CowenReiterated RatingMarket PerformN/A
i
7/29/2016Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
i
5/6/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
(Data available from 3/9/2016 forward)
Sunesis Pharmaceuticals logo
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $5.32
$4.65
$7.08

50 Day Range

MA: $3.25
$2.38
$5.32

52 Week Range

Now: $5.32
$1.12
$11.30

Volume

1,198,965 shs

Average Volume

4,330,995 shs

Market Capitalization

$96.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Sunesis Pharmaceuticals?

The following equities research analysts have issued research reports on Sunesis Pharmaceuticals in the last year: Cowen Inc, HC Wainwright, Oppenheimer Holdings Inc., Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for SNSS.

What is the current price target for Sunesis Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Sunesis Pharmaceuticals in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 69.2%. Oppenheimer Holdings Inc. has the highest price target set, predicting SNSS will reach $12.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Sunesis Pharmaceuticals in the next year.
View the latest price targets for SNSS.

What is the current consensus analyst rating for Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SNSS, but not buy more shares or sell existing shares.
View the latest ratings for SNSS.

What other companies compete with Sunesis Pharmaceuticals?

How do I contact Sunesis Pharmaceuticals' investor relations team?

Sunesis Pharmaceuticals' physical mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is 650-266-3500 and its investor relations email address is [email protected] The official website for Sunesis Pharmaceuticals is www.sunesis.com.